Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lidocaine + ketorolac** is a non-opioid analgesic combination consisting of lidocaine, an amide local anesthetic, and ketorolac, a nonsteroidal anti-inflammatory drug. Lidocaine inhibits neuronal voltage-gated sodium-channel ion flux to prevent initiation and propagation of nociceptive impulses, while ketorolac reversibly inhibits cyclooxygenase-1 and cyclooxygenase-2, reducing prostaglandin-mediated pain and inflammation. The combination has been administered together in local and regional anesthesia, intravenous regional anesthesia, perioperative analgesia, and procedural pain-management settings. In the United States, IT3 Medical markets co-packaged lidocaine hydrochloride and ketorolac tromethamine kits as Acunistat-30 and Acunistat-60 under abbreviated new drug applications. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fad54f13-52a6-4c4b-9120-46bfffe2808e))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + ketorolac.